Last reviewed · How we verify
Dexmedetomidine, midazolam; fentanyl
Dexmedetomidine, midazolam; fentanyl is a Sedative-hypnotic Small molecule drug developed by Hospira, now a wholly owned subsidiary of Pfizer. It is currently in Phase 2 development for Sedation in intensive care unit (ICU) patients, Anesthesia.
Alpha-2 adrenergic receptor agonist
Alpha-2 adrenergic receptor agonist Used for Sedation in intensive care unit (ICU) patients, Anesthesia.
At a glance
| Generic name | Dexmedetomidine, midazolam; fentanyl |
|---|---|
| Sponsor | Hospira, now a wholly owned subsidiary of Pfizer |
| Drug class | Sedative-hypnotic |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Dexmedetomidine acts as an agonist at the alpha-2 adrenergic receptor, producing sedative and analgesic effects. Midazolam is a benzodiazepine receptor agonist, enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA). Fentanyl is a synthetic opioid agonist, binding to opioid receptors in the brain and spinal cord to produce analgesia.
Approved indications
- Sedation in intensive care unit (ICU) patients
- Anesthesia
Common side effects
- Hypotension
- Bradycardia
- Dry mouth
- Dizziness
- Nausea
Key clinical trials
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Attenuate the Stress Response in Laparoscopic Cholecystectomy (PHASE4)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
- Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support
- Effect of Dexmedetomidine on Tear Production in Angioplasty Patients (NA)
- Pharmacokinetics of Drugs Administered to Children
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
- Nurse-Led BIS-Guided Sedation Protocol in Pediatric Intensive Care (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine, midazolam; fentanyl CI brief — competitive landscape report
- Dexmedetomidine, midazolam; fentanyl updates RSS · CI watch RSS
- Hospira, now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about Dexmedetomidine, midazolam; fentanyl
What is Dexmedetomidine, midazolam; fentanyl?
How does Dexmedetomidine, midazolam; fentanyl work?
What is Dexmedetomidine, midazolam; fentanyl used for?
Who makes Dexmedetomidine, midazolam; fentanyl?
What drug class is Dexmedetomidine, midazolam; fentanyl in?
What development phase is Dexmedetomidine, midazolam; fentanyl in?
What are the side effects of Dexmedetomidine, midazolam; fentanyl?
What does Dexmedetomidine, midazolam; fentanyl target?
Related
- Drug class: All Sedative-hypnotic drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: Hospira, now a wholly owned subsidiary of Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Sedation in intensive care unit (ICU) patients
- Indication: Drugs for Anesthesia
- Compare: Dexmedetomidine, midazolam; fentanyl vs similar drugs
- Pricing: Dexmedetomidine, midazolam; fentanyl cost, discount & access